PMOS Clinical Decision Support

01 · Nomenclature & Framing

From PCOS to PMOS

As of the May 2026 Lancet global consensus, the condition is renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change re-centers the diagnosis on the endocrine and metabolic biology your team already treats — it is not cosmetic.

1 in 8

Women affected (~170M worldwide)

~85%

Insulin resistance (clamp) · 75% even in lean

~70%

Remain undiagnosed at any given time

3-yr

Global transition & ICD recoding period

Why the name changed

What to tell patients and the care team

The "cysts" on ultrasound are arrested antral follicles, not pathological cysts — and patients are not more likely to have true ovarian cysts.
The old label drove diagnostic delay, fragmented care, and stigma, and obscured the metabolic and cardiovascular dimensions.
Polyendocrine names the interacting hormonal drivers — insulin, androgens, and neuroendocrine (GnRH/LH) dysfunction.
Metabolic foregrounds insulin resistance and cardiometabolic risk as core, not incidental.
Ovarian is retained for continuity and the reproductive phenotype.

Consensus from 56 organizations and ~22,000 stakeholders. The new, accurate symptom-based name was favored by 86% of patients and 71% of clinicians over keeping the PCOS acronym or a generic name. Diagnostic criteria are unchanged. A managed 3-year transition covers EHR/SNOMED-CT and ICD recoding (via WHO) and integration into the International Guideline's 2028 update — so PCOS billing codes persist in the interim.

The core loop you are treating

Insulin resistance and androgen excess are bidirectional — both must be addressed

Insulin resistance → compensatory hyperinsulinemia (present in ~85%) stimulates ovarian theca-cell androgen synthesis and lowers SHBG (raising free androgen).
Androgen excess → disrupts folliculogenesis (follicular arrest), drives hirsutism, acne, alopecia.
HPO disruption → elevated LH:FSH, increased GnRH pulse frequency, relative LH excess → more thecal androgen.
Adiposity/adipokines → visceral fat amplifies IR; leptin resistance, low adiponectin, IL-6/TNF-α inflammation.

⚑

Clinical anchor. Treating insulin resistance is treating PMOS at its root. On gold-standard euglycemic-clamp studies, IR is present in ~85% overall and ~75% of lean patients (BMI ≤25) — it is intrinsic, not adiposity-driven. Never defer the metabolic workup on the basis of normal weight.

Long-term risk this diagnosis flags

PMOS is a systemic cardiometabolic disorder, not a gynecologic one

4–7×

Type 2 diabetes

2–3×

Metabolic syndrome

1.7–2.5×

CVD 1.68 · MI 2.50 · stroke 1.71 (OR)

3×

Endometrial cancer

Quick reference

Diagnostic criteria and the competing classification systems, at a glance

Rotterdam domain (adults)	Threshold / test
Hyperandrogenism	Clinical (hirsutism mFG ≥4–6, ethnicity-adjusted; acne/alopecia weaker) or biochemical (calculated free T / FAI; total T by LC-MS/MS; DHEAS/androstenedione if T normal)
Ovulatory dysfunction	Cycles <21 or >35 d (or <8/yr) from 3 yr post-menarche; any cycle >90 d; low mid-luteal progesterone confirms
Polycystic morphology	FNPO ≥20 in ≥1 ovary or ovarian volume >10 mL; or elevated assay-specific AMH (adults only)
Diagnostic rule	Any 2 of 3 after excluding mimics. Irregular cycles + hyperandrogenism → no imaging/AMH needed. Adolescents: require both hyperandrogenism and ovulatory dysfunction (no morphology/AMH within 8 yr of menarche)

Classification system	Basis	Types	Status
Rotterdam A–D	HA × ovulatory dysfunction × PCOM (reproductive only)	4	Operative — 2023 Guideline & 2012 NIH
AE-PCOS / Azziz A–G	Splits hyperandrogenism (biochemical vs clinical) × OD × PCOM	7	Defined enumeration; reproductive only (the checker)
Myers–Unfer A–G	Rotterdam features + insulin resistance as 4th axis	7+	Proposal (2023) — not guideline-adopted
Data-driven clusters	Unsupervised ML on endocrine-metabolic variables	3–4	Emerging (Gao Nat Med 2025); not yet adopted

Guidelines & evidence base (what's current)

There is no newer standalone US guideline — US and international practice both run on the 2023 international document

2023 International Evidence-Based Guideline (Teede et al, Eur J Endocrinol) — the operative global standard, developed with ESHRE, ASRM, the AE-PCOS Society and 39 organizations; used in 195 countries; next update 2028.
2025 international adolescent recommendations (Peña et al, BMC Med) — stricter pediatric criteria; no morphology/AMH criterion.
2026 Lancet consensus — rename to PMOS; criteria unchanged.

US landscape: the Endocrine Society's dedicated PCOS guideline (2013) and ACOG bulletin predate the above; the AE-PCOS Society is US-based and co-led the 2023 guideline, which US practice now follows.
Recent literature: Nat Rev Dis Primers 2024 (pathophysiology); multi-ancestry GWAS Nat Genet 2025; global prevalence Hum Reprod Update 2026; CVD meta-analysis JAHA 2024.

Coming in the 2028 update: full incorporation of PMOS terminology; likely formalization of GLP-1 RA positioning in the treatment algorithm; an expanded cardiometabolic-risk framework aligned with the endocrine-metabolic reframing; and enhanced adolescent risk stratification and longitudinal follow-up. The Monash PCOS/PMOS Guideline hub hosts the living documentation and full algorithms.

02 · Pathophysiology

A polyendocrine, multisystem disorder

The rename is biology-led: PMOS is driven by interacting neuroendocrine (brain), metabolic/gut, and immune-inflammatory circuits — not an isolated ovarian problem. Each axis below feeds the others, which is why single-target therapy underperforms.

The self-perpetuating core loop

Three reinforcing drivers — break any one and the others ease

Hyperinsulinemia

IR in ~85% (≥75% of lean). Insulin sensitizes the ovary to LH, drives theca-cell androgen synthesis, and suppresses hepatic SHBG → more free androgen.

Androgen excess

Theca P450c17 overactivity. Androgens impair follicle selection, worsen central neuroendocrine drive, and promote visceral adiposity → more IR.

Neuroendocrine drive

↑ GnRH pulse frequency → relative LH excess → more thecal androgen. Reduced progesterone-negative feedback locks the loop.

🧠

Brain / neuroendocrine

Accelerated GnRH pulsatility raises LH:FSH; low FSH limits aromatase, so androgens aren't converted to estradiol.
KNDy neurons (kisspeptin / neurokinin B / dynorphin) are dysregulated and set the fast GnRH pulse generator.
Arcuate GABA neurons and AgRP/NPY circuits — stimulated by hyperinsulinemia and leptin — amplify GnRH/LH output.
Elevated AMH acts centrally on GnRH neurons, adding to LH drive.
Developmental programming: prenatal/early-life androgen exposure appears to "set" this circuitry (prenatally-androgenized models reproduce the phenotype).
Impaired steroid (progesterone) negative feedback sustains the high-frequency pulse pattern.

🦠

Gut / microbiome

Dysbiosis: reduced α-diversity, altered Firmicutes : Bacteroidetes, depleted Akkermansia muciniphila; correlates with testosterone and HOMA-IR.
Barrier failure (↑ zonulin) → endotoxemia (LPS) → systemic low-grade inflammation and IR.
↓ short-chain fatty acids → ↓ GLP-1 secretion — a mechanistic link to the GLP-1 RA treatment signal.
Bile-acid signaling (TGR5; bile-acid–IL-22 axis) is disrupted, blunting hypothalamic androgen feedback.
Gut–brain axis: microbial GABA/serotonin modulate GnRH via vagal signaling; GABA-producing taxa track with higher LH:FSH.
Experimental probiotics/prebiotics and FMT are investigational — not standard care.

🔥

Inflammation / immunometabolic

Chronic low-grade inflammation: ↑ hsCRP independent of obesity, with IL-6, TNF-α and NF-κB activation.
Adipose dysfunction: visceral fat, leptin resistance, low adiponectin — amplifying IR and androgen output.
Oxidative stress & mitochondrial dysfunction create a self-reinforcing cycle that degrades oocyte quality.
Inflammatory signaling within theca/granulosa cells impairs folliculogenesis (ferroptosis is an emerging mechanism).
Lipopolysaccharide from gut barrier failure is a key upstream inflammatory trigger — tying the gut and immune axes together.

Genetic & developmental origins

~70% heritable (twin studies); strongly polygenic — multi-ancestry GWAS (2025) implicate neuroendocrine, metabolic, and gonadotropin pathways.
DENND1A and loci in insulin signaling, steroidogenesis, and PI3K-Akt recur across studies.
Epigenetic programming (DNA methylation in granulosa cells; fetal androgen exposure) links environment to phenotype.
Functional ovarian hyperandrogenism (exaggerated 17-OHP response) is present in ~2/3; a minority have an adrenal-predominant source.

Why this matters at the bedside

Treat the metabolic root: insulin-sensitizing therapy and weight management improve all downstream axes — the rationale for metformin, GLP-1 RA, and lifestyle as first-line.
Lean ≠ low-risk: IR and the inflammatory/neuroendocrine drivers are intrinsic, not adiposity-dependent.
The GLP-1 signal is mechanistic, not just weight-mediated — gut–incretin biology is part of the disease.
Multisystem framing justifies the team model: metabolic, dermatologic, reproductive, and psychological care in parallel.

Sources: Stener-Victorin et al. Nat Rev Dis Primers 2024; recent gut-microbiome & neuroendocrine reviews 2024–2026; multi-ancestry GWAS, Nat Genet 2025. See References.

03 · Diagnostic Workup

Criteria, phenotype & exclusions

Diagnosis still rests on the Rotterdam criteria (2 of 3) after exclusion of mimics. The 2023 guideline permits elevated AMH as an alternative to ultrasound for the follicular-morphology criterion in adults.

Diagnosis & phenotype checker

Diagnosis = Rotterdam 2-of-3 (per 2023 Guideline); phenotype = AES 7-class (A–G). Toggle the four features.

Biochemical hyperandrogenemia↑ calculated free T / FAI / total T (LC-MS/MS), DHEAS, or androstenedione

Clinical hyperandrogenismHirsutism (mFG ≥4–6, ethnicity-adjusted), acne, or androgenic alopecia

Ovulatory dysfunctionOligo-/anovulation; <21 or >35 d (or <8/yr) from 3 yr post-menarche; any cycle >90 d. Low mid-luteal progesterone confirms even with regular-appearing cycles.

Polycystic ovarian morphologyFNPO ≥20 in ≥1 ovary OR ovarian vol >10 mL; or elevated assay-specific AMH (adults only)

Insulin resistance / metabolic dysfunction metabolic axis↑ HOMA-IR, impaired glucose tolerance/IFG, or metabolic-syndrome features. Overlay only — does not change the A–G letter, but adds the metabolic axis (Myers–Unfer 2023 intent).

○

Select features present

—

Hyperandrogenism = biochemical or clinical. Diagnosis needs 2 of 3 Rotterdam domains after excluding mimics. In adolescents require both hyperandrogenism and ovulatory dysfunction — morphology/AMH is not a criterion within 8 yr of menarche.

Must-exclude differential

PMOS remains a diagnosis of exclusion — clear these before labeling

Pregnancy — urine/serum hCG before any workup or prescribing.
Thyroid dysfunction — TSH (mimics menstrual irregularity).
Hyperprolactinemia — prolactin.
Nonclassic CAH — early-AM follicular 17-OHP; >200 ng/dL → ACTH stimulation. high-yield miss in fertility patients
Androgen-secreting tumor — rapid virilization, total T >150 ng/dL, or DHEAS >700 µg/dL → imaging.
Cushing syndrome — if stigmata present (AM cortisol / dexamethasone suppression / late-night salivary).
Functional hypothalamic amenorrhea — low LH/FSH, low BMI, high training load.
Primary ovarian insufficiency — high FSH, low AMH + amenorrhea.

Differential AMH tip: very low AMH + amenorrhea points to POI; very high AMH + amenorrhea supports PMOS.

The seven phenotypes (AE-PCOS / Azziz 2009 — A–G)

This checker uses the Azziz 2009 enumeration: four features — biochemical hyperandrogenemia (H_b), clinical hirsutism (H_c), oligo-anovulation (O), polycystic morphology (P). All A–G require some hyperandrogenism. This is a different "A–G" from the Myers–Unfer 2023 proposal (which adds insulin resistance as a 4th axis — see Classification landscape below).

A · Complete

Classic, most common

H_b+H_c+O+P

All four features. Highest IR & cardiometabolic risk.

B · Non-PCOM classic

Anovulatory, no morphology

H_b+H_c+O

Metabolic risk comparable to A.

C · Biochemical+PCOM

Anovulatory, no overt hirsutism

H_b+O+P

Androgen excess biochemical only.

D · Biochemical only

Anovulatory, no hirsutism/PCOM

H_b+O

Diagnosed on labs + cycles.

E · Clinical+PCOM

Hirsute, normal measured androgens

H_c+O+P

Check assay/free-T method before calling androgens "normal."

F · Clinical only

Hirsute, no PCOM, normal labs

H_c+O

Overlaps idiopathic hirsutism — exclude carefully.

G · Ovulatory

Regular cycles

H_b+H_c+P

Hyperandrogenic but ovulatory; milder metabolic profile.

Outside A–G

Normoandrogenic

O+P only

Meets Rotterdam ("classic phenotype D") but excluded from the hyperandrogenism-required AES set.

Letter-collision warning: the AE-PCOS/Azziz A–G labels here are not the same as the older Rotterdam A–D labels (where "D" = the non-androgenic phenotype). Document the component features alongside the letter to avoid ambiguity. Across phenotypes, the hyperandrogenic/anovulatory clusters (A, B) carry the greatest IR, dyslipidemia and T2D burden; ovulatory (G) and normoandrogenic variants are mildest. Phenotype tends to attenuate with age (falling androgens, rising FSH).

Beyond A–D: the classification landscape (emerging)

Three paradigms now coexist. The convergent signal across data-driven studies: the fundamental axis of heterogeneity is metabolic vs reproductive — which the reproductive-only A–D system omits.

Rotterdam A–D

Operative · 2023 Guideline & 2012 NIH

Four phenotypes from HA × OD × PCOM. A metabolic gradient exists by HOMA-IR: A (3.59) > D (2.73) > B (2.59) > C (2.05); IR ~57.5% and phenotype-dependent (Szkodziak 2025).

AE-PCOS / Azziz A–G

Phenotype enumeration (2009)

Splits biochemical vs clinical hyperandrogenism → 7 hyperandrogenic cells (the checker above). Granular, but still reproductive/endocrine — no metabolic axis.

Myers–Unfer A–G

Proposal · Trends Endocrinol Metab 2023

Adds insulin resistance as a 4th axis to Rotterdam → up to 7+ combinations, to direct insulin-sensitizing therapy by metabolic phenotype. Not guideline-adopted (guideline notes clinical IR assays are inaccurate).

Recommended use: for diagnosis, stay with Rotterdam (operative/guideline); for phenotyping, the Azziz A–G above is the only defined, enumerable A–G (the checker). Then adopt the intent of the latest A–G (Myers–Unfer 2023) by always recording the insulin-resistance / metabolic axis alongside the letter — toggle "IR / metabolic dysfunction" in the checker. The key difference: Azziz A–G splits hyperandrogenism (biochemical vs clinical) into 7 reproductive cells; Myers–Unfer A–G instead keeps Rotterdam's three features and adds IR as a 4th axis. Don't report a "Myers–Unfer letter" as validated — it's a proposal without a fixed enumeration — but do let the IR axis drive therapy, which is exactly what the data-driven clusters below support.

Data-driven subtypes — Gao et al, Nature Medicine 2025

Unsupervised clustering of 9 variables in 11,908 women, validated across 5 cohorts with 6.5-yr follow-up — four reproducible subtypes with distinct trajectories:

Hyperandrogenic

25% · ↑T/DHEA-S, mild metabolic

Highest 2nd-trimester loss & dyslipidemia incidence.

Obesity

26% · ↑BMI/glucose/insulin

Most severe metabolic (T2D 7.9%, dyslipidemia 75.3%, HTN 28.7%); lowest IVF live birth — but highest remission.

High-SHBG

26% · ↑SHBG, lowest BMI

Most favorable reproductive outcomes; lowest diabetes/hypertension.

High-LH/AMH

23% · ↑LH, FSH, AMH

Greatest OHSS risk; lowest remission rate.

Converging evidence: independent clustering studies repeatedly resolve a metabolic-vs-reproductive split — van der Ham (JCEM 2024, 3 subtypes), Burns (Front Endocrinol 2025, "may be separate disorders"), Ho (Fertil Steril 2026, MD/MS/NR clusters; MD lowest live birth 44.8% vs 59.3%, GDM 33%), and Wang (Front Endocrinol 2026: IR independently fuels the hyperandrogenic phenotype, HOMA-IR aOR 1.35 with BMI non-significant, while neuroendocrine factors dominate non-hyperandrogenic cases). Where the field stands: A–D remains the operative diagnostic system; these subtypes are not yet guideline-adopted, but they point toward subtype-/IR-tailored therapy, and the PMOS rename is an opportunity to fold the metabolic dimension into future phenotyping.

05 · Management

Goal-directed treatment

Goals: restore menstrual regularity · reduce androgen excess · treat insulin resistance · meet reproductive goals · prevent long-term cardiometabolic disease. Lifestyle is first-line therapy, not an adjunct.

▲

Lifestyle as medicine. A 5–10% weight reduction restores ovulation in 55–100% of anovulatory patients. Quantify it, prescribe it, and monitor it like a drug — and pursue visceral-fat reduction and insulin sensitivity even when the scale does not move (especially in lean phenotypes).

Treatment framework — four escalating tiers

Tiers run in parallel, not strict sequence — match to the patient's dominant goal (symptoms, metabolic risk, or fertility)

Tier 1 · Foundation

Lifestyle as therapy — nutrition, activity, sleep, behavioral & emotional health for all patients, lifelong.

Tier 2 · Symptom-targeted

CHC, progestogen, spironolactone, metformin — cycle/endometrial protection, hyperandrogenism, metabolic features.

Tier 3 · Weight / metabolic

GLP-1 RA, orlistat, bariatric surgery — adjuncts to lifestyle for higher weight (guideline-supported).

Tier 4 · Fertility

Ovulation induction ladder — letrozole first-line → escalation → IVF/ICSI.

Phenotype- & cluster-tailored treatment matrix

Maps the dominant subtype (Gao clusters / Azziz phenotype) to therapy emphasis. Mechanism- and association-driven, hypothesis-generating — no trial has randomized by these subtypes. Individualize with shared decision-making.

Dominant subtype	Key features	Therapy emphasis (non-fertility)	Fertility approach	Watch-outs
Hyperandrogenic Gao HA · Azziz A–C	↑ testosterone/DHEA-S, hirsutism; mild–moderate metabolic	CHC + spironolactone for androgen symptoms; lifestyle; add metformin ± GLP-1 RA if IR axis present (regardless of BMI)	Letrozole first-line	↑ 2nd-trimester loss & dyslipidemia (Gao); anti-androgens require contraception
Obesity / metabolic Gao Obesity	↑ BMI, glucose, insulin; T2D 7.9%, dyslipidemia 75.3%, HTN 28.7%	Weight-centric: lifestyle + GLP-1 RA / tirzepatide; metformin; consider bariatric at lower BMI; aggressive CV/T2D/lipid screening	Optimize weight first, then letrozole; highest remission with weight loss	Lowest IVF live-birth — optimize preconception; contraception with GLP-1/bariatric
High-SHBG Gao SHBG	↑ SHBG, lowest BMI, lower LH/T; most favorable	Lightest touch: lifestyle; cycle regulation (CHC / cyclic progestogen) as needed; minimal metabolic pharmacotherapy	Most favorable outcomes; standard care	Avoid over-treatment; still screen metabolically per guideline
High-LH/AMH Gao LH/AMH	↑ LH, FSH, AMH; high follicle count	Cycle regulation; lifestyle	Letrozole → low-dose step-up gonadotropins; IVF with antagonist + agonist trigger + freeze-all; adjunct metformin to ↓ OHSS	Greatest OHSS risk; lowest remission — counsel
Normoandrogenic Rotterdam D / ovulatory	No/minimal androgen excess; milder metabolic profile	Endometrial protection (cyclic progestogen / CHC) if oligomenorrheic; lifestyle; lower drug burden	Often ovulatory or responds to lifestyle / letrozole	Ensure endometrial protection with long cycles; reassess over time

Cross-cutting IR overlay: for any subtype with the insulin-resistance / metabolic axis (checker toggle), add or intensify insulin-sensitizing therapy — lifestyle + metformin ± GLP-1 RA — regardless of BMI. This is the practical expression of the "latest A–G" (Myers–Unfer) intent and the convergent cluster evidence. Caveat: subtype-directed therapy is not yet guideline-endorsed; use as a reasoning aid alongside the 2023 Guideline, not a substitute.

Tier 1–2 · Symptom-targeted therapy

Menstrual & endometrial protection

Goal: ≥4 withdrawal bleeds/year to protect the endometrium

1st

Combined hormonal contraceptive — cycle control + androgen suppression.

alt

Cyclic progestogen 10–14 d/cycle if CHC contraindicated.

alt

LNG-IUD — contraception + endometrial protection.

Hyperandrogenism

Goal: reduce hirsutism, acne, androgenic alopecia

1st

CHC with anti-androgenic progestin (drospirenone, norgestimate).

add

Spironolactone 25–100 mg/d (2023 guideline range — lower adverse-effect risk; higher doses used in practice). Off-label; requires reliable contraception. Add after ≥6 mo of COCP/cosmetic if response suboptimal.

adj

Laser/light therapy (evidence-based for facial hirsutism + QoL) & topical eflornithine. Finasteride (hepatotoxicity risk) for alopecia; avoid cyproterone ≥10 mg (meningioma) and flutamide/bicalutamide (severe hepatotoxicity).

Insulin resistance / metabolic

Goal: treat PMOS at its root

1st

Metformin — improves cycle regularity, modest androgen + weight benefit; first-line IR agent.

emerg

GLP-1 RA — greater weight loss + insulin-sensitivity gains than metformin, with ↓testosterone and improved ovulation. Not yet approved for PMOS itself; justified for comorbid approved indications (obesity, T2D, OSA, HF). Avoid peri-conception.

adj

Inositol — modest metabolic benefit, limited clinical benefit (see Supplements below); statin for dyslipidemia; ACEi/ARB for hypertension.

Fertility / ovulation induction

Goal: achieve ovulation & pregnancy

1st

Letrozole (aromatase inhibitor) — superior live-birth vs clomiphene in PMOS.

alt

Clomiphene — alternative; higher multiple-pregnancy rate.

adj

Metformin + OI modest benefit (esp. non-obese); gonadotropins / IVF → refer reproductive endocrinology.

Lifestyle prescription — quantified targets

Nutrition

No single "PMOS diet" — adherence dominates outcomes.
Low-GI / Mediterranean pattern: ↓IR, ↓androgens, ↓inflammation.
Protein 1.2–1.6 g/kg for satiety + lean mass.
Limit ultra-processed foods, added sugar, refined carbs.

Exercise

≥150 min/wk moderate + 2×/wk resistance.
Resistance training improves IR independent of weight loss.
HIIT ≥ MICT for IR and androgens.
Target visceral fat — outcomes track this over scale weight.

Behavioral & sleep

Screen depression/anxiety every visit (2–3× prevalence).
CBT / acceptance-based therapy is evidence-based.
Treat OSA/insomnia — sleep loss worsens IR.
Motivational interviewing for durable change.

See the dedicated Supplements card below for evidence-graded guidance (inositol, berberine, vitamin D, omega-3, NAC). Position all as adjuncts to lifestyle, never substitutes.

Tier 3 · Weight management & metabolic optimization

2023 Guideline (rec 4.5, 4.9): anti-obesity pharmacotherapy and bariatric surgery as adjuncts to lifestyle for higher-weight PMOS, per general-population guidelines

Anti-obesity pharmacotherapy

opt

GLP-1 RA (liraglutide, semaglutide) & orlistat — added to lifestyle for higher weight. Tirzepatide (GLP-1/GIP) used under obesity/T2D indications.

safety

Effective contraception mandatory — GLP-1 RAs are not pregnancy-safe; ~2-month washout before conception for semaglutide. Gradual dose escalation to limit GI effects.

note

High weight-regain risk after stopping; counsel on likely long-term use and the absence of PMOS-specific long-term safety data.

Bariatric / metabolic surgery

opt

Improves weight, BP, glycemia, hirsutism, cycle regularity, ovulation and pregnancy rates; follow general-population criteria.

access

PMOS is a metabolic condition and may qualify at a lower BMI threshold, analogous to type 2 diabetes.

safety

Counsel on rapid return of fertility — continue contraception until weight stable (usually ~1 year) to avoid adverse pregnancy outcomes.

GLP-1 / GIP agents — the emerging evidence

Mechanistically central given insulin resistance is the disease root — but not yet first-line guideline therapy; used under existing obesity/T2D indications

~75%

IR prevalence (93.9% with obesity · 59.3% normal-weight)

−18%

Visceral fat · liraglutide 26 wk (liver fat −44%, weight −5.6%)

↑↑

Menstrual frequency & spontaneous pregnancy (meta-analysis, p<0.001)

4×

Tirzepatide share of GLP-1-treated PMOS, 2022→25 (0.7→2.8%)

Liraglutide 3.0 mg × 32 wk improved HOMA-IR, OGTT-derived insulin sensitivity, early insulin response, FAI, and menstrual frequency vs placebo (Elkind-Hirsh).
GLP-1 RA + metformin is emerging as the preferred regimen for the combined hyperandrogenic + metabolic phenotype (higher ovulation rates than comparators).
Real-world tirzepatide (n≈4,200, ObesityWeek 2025): >90% achieved ≥10% weight loss by 10 months; mean ~18.8%.

Improvements in ovulation/pregnancy track with the degree of IR and weight reduction — consistent with the metabolic-root model.
Caveats: evidence base still low-to-moderate certainty; no proven live-birth benefit; pregnancy-unsafe; weight regain on cessation.
Truveta real-world data are preliminary/non-peer-reviewed; ~98% of GLP-1-treated PMOS patients also carried obesity/T2D (i.e., prescribed on existing indications).

Sources: 2025 systematic review, Ther Adv Endocrinol Metab; GLP-1 RA narrative review, Endocr Connect 2025; ObesityWeek 2025 real-world tirzepatide cohort; Truveta utilization analysis 2025. See References.

Tier 4 · Ovulation-induction ladder (fertility goal)

2023 Guideline infertility algorithm — exclude pregnancy, optimize preconception (weight, BP, OGTT, folate) first; agents are off-label in many countries

1st line

Letrozole — confirmed first-line (superior ovulation, clinical pregnancy, and live-birth rates vs clomiphene; strong recommendation, high-quality evidence). Increase dose as needed.

2nd line

Clomiphene citrate ± metformin — alternative oral OI; clomiphene+metformin improves ovulation/pregnancy over either alone. Higher multiple-pregnancy rate; monitor.

2nd line

FSH gonadotropins — low-dose step-up protocol; intensive ultrasound monitoring; cancel cycle if >2 follicles >14 mm to avoid multiples.

2nd line

Laparoscopic ovarian surgery — option for clomiphene-resistant cases with no other infertility factors; weigh surgical/anesthetic risk.

3rd line

IVF / ICSI — after first/second-line failure. GnRH-antagonist protocol preferred; agonist trigger + freeze-all to cut OHSS; adjunct metformin if agonist long protocol used. Single-embryo transfer standard. Consider IVM where OHSS risk is high.

Counsel on OHSS risk (elevated AMH predicts it) and the rapid return of fertility after weight loss/surgery. Refer to reproductive endocrinology for gonadotropins/IVF.

Pregnancy & preconception care

PMOS is a high-risk pregnancy condition — flag the diagnosis in antenatal records and monitor. All points below are guideline recommendations (2023 Guideline §1.9, 4.10–4.11, 5.1).

Increased pregnancy risks

Gestational diabetes — screen proactively.
Hypertensive disorders / pre-eclampsia.
Miscarriage and preterm birth.
IUGR / small-for-gestational-age / low birth weight.
Higher gestational weight gain; ↑ caesarean rate.
Not increased: macrosomia / large-for-gestational-age / instrumental delivery. ART confers no excess risk over non-PMOS.

Preconception optimization

OGTT + blood pressure before pregnancy / fertility treatment.
Folate — higher dose if BMI >30; routine preconception care.
Weight, smoking, alcohol, nutrition, activity, sleep, mental & sexual health.
Optimize pre-existing diabetes, hypertension, thyroid, mental health.
Reproductive life plan; early lifestyle support offered in pregnancy.

Glycemic screening in pregnancy

all

75-g OGTT preconception for all with PMOS planning pregnancy / fertility treatment.

then

If not done preconception → first antenatal visit, and repeat at 24–28 weeks.

Other PMOS medications

stop

GLP-1 RA — not pregnancy-safe; stop with effective contraception, ~2-mo washout (semaglutide) before conception.

stop

Anti-androgens (spironolactone) — risk of male-fetus undervirilization; stop, ensure contraception. Letrozole — stop once pregnancy confirmed.

Metformin in pregnancy — the nuanced answer to "stay on it": the guideline is clear that metformin does not prevent gestational diabetes, late miscarriage, hypertension/pre-eclampsia, or macrosomia (EBR 4.11.1). It may be considered in select circumstances (e.g., elevated preterm-birth risk) to reduce preterm delivery and limit excess gestational weight gain (EBR 4.11.2), and is continued per diabetes-in-pregnancy guidance when there's a glycemic indication. So continuation is a shared-decision, indication-driven choice — not a routine measure to prevent the complications above. Counsel that long-term offspring effects are unclear (a signal toward higher childhood weight, causality uncertain); GI side effects are mild and no worse in pregnancy.

Supplements — what the evidence supports

2023 Guideline grades inositol as low-evidence/limited-benefit; berberine is not addressed by any major guideline. Frame all as adjuncts and counsel on supplement-grade quality/regulation.

Inositol (myo- ± D-chiro) 2023 Guideline: EBR, ⊕◯◯◯ low

"Could be considered" per patient preference — limited harm, possible improvement in some metabolic measures, but limited clinical benefit for ovulation, hirsutism, or weight. Metformin preferred over inositol for hirsutism/central adiposity (though more GI effects). Experimental for fertility — not recommended as a fertility therapy. Specific dose/form can't be guideline-endorsed (commonly studied: myo-inositol 2 g BID ± D-chiro 50 mg, 40:1).

Berberine not in guideline · small RCTs/MA

Meta-analyses suggest insulin-sensitizing, lipid-lowering, and androgen/LH:FSH-reducing effects, broadly comparable to metformin in small trials — but evidence is low quality and no solid effect on live birth. Cautions: supplement-grade quality varies; CYP3A4/P-glycoprotein drug interactions; GI effects; contraindicated in pregnancy/lactation (bilirubin displacement → kernicterus risk) — stop before conception. Typical study dose ~0.5 g TID. Not a recommended therapy; know it because patients use it.

Vitamin D replete deficiency

Correct documented deficiency (general-population practice); may modestly support metabolic measures. Not a PCOS-specific therapeutic.

Omega-3 (EPA+DHA) adjunct

Anti-inflammatory; may lower triglycerides and androgens modestly. Reasonable adjunct, especially with dyslipidemia.

N-acetylcysteine / magnesium weak/adjunct

NAC: antioxidant with mixed ovulatory data; magnesium if deficient. Low-priority adjuncts.

Shared counseling point (guideline practice point): supplement regulation and quality control differ from pharmaceuticals — dose, purity, and combinations vary by product. Ask patients to disclose all supplements, and document shared decision-making.

06 · Lifestyle & Supplement Decision Support

Evidence-based, weight-inclusive optimization

Lifestyle is the one therapy recommended for every patient, lifelong. Supplements are adjuncts — most carry low-certainty evidence — so target them to phenotype and trial them deliberately.

Lifestyle prescription — by domain

△

Nutrition

No single “PMOS diet” — no composition beats another (guideline EBR). Pick a sustainable pattern; Mediterranean-style suits many.
Emphasize fiber, protein, whole foods; limit refined carbs & sugary drinks.
Tailor to preferences/culture; avoid restrictive diets — screen for disordered eating at any weight.
Health benefits accrue even without weight loss.

⚡

Physical activity

150–300 min/wk moderate (or 75–150 vigorous) + resistance ×2/wk — prevention.
≥250 min/wk moderate for weight management / regain prevention.
Resistance training independently improves IR & body composition.
Reduce sedentary time; any activity beats none.

☽

Sleep

Screen & treat OSA — markedly more prevalent in PMOS, independent of BMI.
Short/poor sleep worsens IR & appetite regulation.
Sleep-hygiene targets; refer for a sleep study if symptomatic.

♥

Behavioral & emotional

Behavioral support: goal-setting, self-monitoring, SMART goals, relapse prevention.
Screen depression & anxiety (high prevalence); CBT helps adherence and symptoms.
Motivational interviewing improves engagement and durability of change.

⚖

Weight approach — weight-inclusive

5–10% loss restores ovulation in 55–100% of anovulatory patients — but pursue visceral-fat/IR gains even when the scale doesn’t move.
Offer weight-inclusive (healthy-behavior) or weight-centric care per patient preference.
Ask permission to weigh; use non-stigmatizing language; consider blind weighing.

Supplement decision support — evidence-graded

Filter by therapeutic goal to highlight agents with a signal. Evidence grades: MOD moderate · LOW low · V-LOW very low certainty · NEG no benefit · STD standard care. Click any row for the GRADE rationale.

Supplement	Best-supported use	Studied dose	Evidence	Cautions / interactions
Myo-inositol (± D-chiro 40:1)	↓ IR (HOMA-IR SMD −0.81), ↑ SHBG; DCI may aid ovulation	MI 2 g BID ± DCI 50 mg	MOD metabolic; LOW clinical	Mild GI (< metformin); quality varies; experimental for fertility
Vitamin D	Correct deficiency (67–85% deficient); ↑ IR markers, glucose, mood	Replete to sufficiency (e.g., 1000–4000 IU/d)	LOW (best if deficient)	Check level; avoid megadosing
Omega-3 (EPA+DHA)	Dyslipidemia (LDL SMD −9.6, HDL +2.3), anti-inflammatory, modest ↓ androgens/TG	1–3 g/d EPA+DHA	LOW	Bleeding risk at high dose; oxidation/quality
Probiotics / synbiotics	↓ CRP (SMD −0.82); modest IR & androgen improvement via gut	Multi-strain, 8–12 wk	LOW (short, heterogeneous)	Strain-dependent; caution if immunocompromised
Berberine	Metformin-like: ↓ IR/lipids/androgens; cycle regularity	0.5 g TID (or phytosome 550 mg BID)	LOW (≈ metformin)	Contraindicated in pregnancy/lactation; CYP3A4/P-gp interactions; GI
N-acetylcysteine (NAC)	Adjunct to letrozole → more follicles, modest ↑ pregnancy (OR ~2.15)	600 mg BID–TID	V-LOW	GI; limited pregnancy-safety data
Coenzyme Q10	↓ IR/lipids; oocyte/ART outcomes (OR ~2.49 pregnancy)	100–200 mg/d	V-LOW fertility	Well-tolerated; may potentiate warfarin
L-carnitine	Endocrine-metabolic signal; pregnancy OR very large but fragile	250 mg–3 g/d	V-LOW (small trials)	GI; interpret huge OR cautiously
Melatonin	Oocyte quality; pregnancy OR ~1.66 in ART	3 mg nightly	V-LOW	Sedation; use only with clear indication
Spearmint tea	Specific anti-androgen: ↓ free T, hirsutism	2 cups/day	LOW (small trials)	Minimal; well tolerated
Curcumin	↑ insulin sensitivity, ↓ glucose & inflammatory markers	500–1500 mg/d (bioavailable form)	LOW	Poor absorption; anticoagulant interaction; mild GI
Alpha-lipoic acid (ALA)	↓ fasting glucose (SMD −0.60) & HOMA-IR (SMD −2.03; high heterogeneity); antioxidant/anti-inflammatory. No clear androgen/lipid effect.	600–1200 mg/d	MOD FBG; LOW HOMA-IR	May lower glucose (watch with insulin/sulfonylurea); GI; often combined with inositol
Chromium (picolinate)	↓ IR (SMD −0.84), ↓ fasting insulin & BMI; ovulation improved in a 6-mo RCT	200–1000 µg/d	LOW (mixed)	Some MAs show ↑ total/free T (SMD +0.36/+0.80) — caution in hyperandrogenic phenotype; short-term use
Resveratrol	↓ total testosterone & DHEAS; ↓ insulin / improved sensitivity (small RCTs)	~800 mg–1.5 g/d	LOW	Bioavailability; theoretical estrogenic activity; quality varies
Quercetin	↓ testosterone & LH; ↓ IR, ↑ adiponectin (emerging RCTs)	500–1000 mg/d	LOW	CYP/drug interactions; supplement quality
Zinc	↓ insulin/IR; improved hirsutism & alopecia; deficiency common	30–50 mg/d (short term)	LOW	Copper depletion with prolonged high dose
Vitamin E	Antioxidant; ↓ oxidative stress, modest androgen/IR signal — usually co-supplemented	~400 IU/d	LOW (co-supp)	Bleeding risk at high dose; hard to isolate effect
Cinnamon	Modest ↓ fasting glucose/IR; some cycle-regularity signal	1–1.5 g/d	V-LOW	Prefer Ceylon — cassia coumarin is hepatotoxic at high dose
Selenium	Mixed: some ↓ insulin/CRP, but inconsistent and possible adverse lipid/glycemic signals	~200 µg/d	V-LOW (mixed)	Narrow safety window; avoid if replete (selenosis)
Folate (preconception)	All patients planning pregnancy; ↓ homocysteine	0.4–5 mg/d (higher if BMI >30)	STD preconception	Routine preconception care
Vitamin B12	Monitor & replete if on long-term metformin	Per level	STD monitoring	Metformin lowers B12 over time
Magnesium	No PMOS-specific benefit — replete only if deficient	—	NEG (2024 MA)	De-prioritize unless documented deficiency

Decision principles: supplements are adjuncts, not substitutes for lifestyle and indicated medical therapy. Most evidence is low/very-low certainty (small trials, frequent co-supplementation). Pick 3–4 agents targeted to the phenotype, trial for ~3 months, then reassess against labs/symptoms. Skip multi-ingredient “PCOS blends” in favor of single agents at studied doses. Counsel on supplement-grade quality/regulation, ask patients to disclose everything they take, and stop berberine (and review others) before conception.

Gut microbiome — role & microbiome-targeted interventions

An emerging, mechanistically central axis: dysbiosis links to insulin resistance, hyperandrogenism and inflammation. Interventions are promising but evidence is still low-certainty and non-standardized.

Why it matters

Dysbiosis: reduced α-diversity, altered Firmicutes : Bacteroidetes, depleted Akkermansia — correlates with testosterone & HOMA-IR.
SCFA depletion → less GLP-1/PYY signaling and weaker gut-barrier integrity.
↑ permeability (zonulin) → LPS endotoxemia → TLR4/NF-κB inflammation → IR & androgens.
Bile-acid–IL-22 and microbial-GABA gut–brain pathways modulate ovarian function.

Interventions (graded)

1st

Diet & fiber — Mediterranean/DASH + fermentable fiber raise SCFAs and diversity; the highest-yield, lowest-risk lever. LOW

add

Synbiotics > probiotics > prebiotics — synbiotics (e.g., L. acidophilus/casei + B. bifidum + inulin, 12 wk) ↓ HOMA-IR & insulin, ↑ SHBG, ↓ total T; probiotics ↓ CRP (SMD −0.82). LOW

exp

Fecal microbiota transplant (FMT) — mostly animal/early data; experimental, not for clinical use. V-LOW

Strain, dose and duration are not standardized — frame microbiome therapy as a diet-first strategy with synbiotics as a reasonable 8–12-week adjunct in IR/hyperandrogenic phenotypes, and treat FMT/postbiotics as research-stage. Sources: Shamasbi 2020 & overview of SRs; Front Microbiol/Endocrinol 2024–2026.

07 · Team-Based Documentation

Role-specific note templates

Shared workflow: EMR documentation · RPM/CCM touchpoints · one shared care plan · warm handoffs. Select a role, edit the placeholders, and copy into your EMR. Replace [bracketed] fields.

PCP / Endocrinology — diagnosis & medical management

Owns: diagnosis, labs, pharmacotherapy, cardiometabolic risk, referrals, annual review

Registered Dietitian — medical nutrition therapy

Owns: nutrition assessment, individualized pattern, disordered-eating screen, supplement guidance

Health Coach — behavior change & monitoring

Owns: exercise Rx, adherence, biometrics/CGM, sleep & stress coaching, between-visit bridge

Psychology — behavioral health

Owns: mood/anxiety, eating-behavior assessment, body image, CBT/ACT, coordination

08 · Monitoring & Referral

Surveillance cadence & handoffs

PMOS is a lifelong cardiometabolic condition — structure the follow-up like chronic-disease management.

Monitoring cadence

Every visit

BP, weight, waist circumference; menstrual regularity; medication adherence; mood screen (PHQ/GAD).

3–6 mo

Fasting glucose/insulin/HOMA-IR; androgen panel if on therapy; behavioral-goal review.

Annually

Fasting lipids, hepatic panel if overweight/obese (MASLD); reassess reproductive goals; endometrial-protection review. Counsel to report any abnormal bleeding — routine endometrial-thickness ultrasound is not recommended in asymptomatic patients.

Q1–3 yr

75 g OGTT (preferred over HbA1c) for all patients regardless of weight — high T2D conversion; HbA1c less sensitive in PMOS.

As needed

Repeat pelvic US not routinely required; repeat labs per symptom/treatment change.

When to refer

🧬

Reproductive endocrinology≥2 failed letrozole OI cycles; IVF; co-existing infertility.

🔬

Ob/GynEndometrial biopsy if anovulation >1 yr or abnormal bleeding.

💠

DermatologySevere/refractory hirsutism, acne, or alopecia.

🧠

Behavioral health / psychiatrySignificant mood disorder or eating-disorder comorbidity.

😴

Sleep medicineOSA symptoms — 5–30× more prevalent in PMOS.

⚕️

EndocrinologyAtypical presentation, ↑17-OHP, suspected Cushing/adrenal tumor.

Pre-conception: optimize metabolic status 3–6 mo before conception; folic acid; early GDM screening (3× risk); flag preeclampsia/preterm risk → high-risk OB.

Special populations

Adolescents

Require HA and OA; morphology not a criterion within 8 yr of menarche. Lifestyle first; screen disordered eating early; avoid premature labeling.

Lean / normal-weight

20–30% of patients; often delayed. Always check HOMA-IR. Prioritize diet quality + exercise over weight loss.

Perimenopause

Androgenic symptoms may ease; metabolic risk accelerates → aggressive CV risk management. Continue cycle protection until menopause confirmed.

Pregnancy

3× GDM risk → early screen; higher HTN/preeclampsia/preterm risk; metformin may reduce early miscarriage in some.

From PCOS to PMOS

Why the name changed

The core loop you are treating

Long-term risk this diagnosis flags

Quick reference

Guidelines & evidence base (what's current)

A polyendocrine, multisystem disorder

The self-perpetuating core loop

Hyperinsulinemia

Androgen excess

Neuroendocrine drive

Brain / neuroendocrine

Gut / microbiome

Inflammation / immunometabolic

Genetic & developmental origins

Why this matters at the bedside

Criteria, phenotype & exclusions

Diagnosis & phenotype checker

Select features present

Must-exclude differential

The seven phenotypes (AE-PCOS / Azziz 2009 — A–G)

A · Complete

B · Non-PCOM classic

C · Biochemical+PCOM

D · Biochemical only

E · Clinical+PCOM

F · Clinical only

G · Ovulatory

Outside A–G

Beyond A–D: the classification landscape (emerging)

Rotterdam A–D

AE-PCOS / Azziz A–G

Myers–Unfer A–G

Data-driven subtypes — Gao et al, Nature Medicine 2025

Hyperandrogenic

Obesity

High-SHBG

High-LH/AMH

Panel, interpretation & calculators

Calculated free testosterone

HOMA-IR & Free Androgen Index

Recommended panel & interpretation

Androgen panel

Metabolic panel

Reproductive / exclusion

Lab workflow: order → boilerplate → patient discussion

1 · Structured order set

2 · Results → interpretation + discussion

Goal-directed treatment

Treatment framework — four escalating tiers

Tier 1 · Foundation

Tier 2 · Symptom-targeted

Tier 3 · Weight / metabolic

Tier 4 · Fertility

Phenotype- & cluster-tailored treatment matrix

Tier 1–2 · Symptom-targeted therapy

Menstrual & endometrial protection

Hyperandrogenism

Insulin resistance / metabolic

Fertility / ovulation induction

Lifestyle prescription — quantified targets

Tier 3 · Weight management & metabolic optimization

Anti-obesity pharmacotherapy

Bariatric / metabolic surgery

GLP-1 / GIP agents — the emerging evidence

Tier 4 · Ovulation-induction ladder (fertility goal)

Pregnancy & preconception care

Increased pregnancy risks

Preconception optimization

Glycemic screening in pregnancy

Other PMOS medications

Supplements — what the evidence supports

Evidence-based, weight-inclusive optimization

Lifestyle prescription — by domain

Nutrition

Physical activity

Sleep

Behavioral & emotional

Weight approach — weight-inclusive

Supplement decision support — evidence-graded